


# AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims

1. (previously presented) A compound of the Formula A:



wherein:

a is 0 or 1; b is 0 or 1; m is 0, 1 or 2; n is 0, 1, 2 or 3; p is 0, 1 or 2; q is 0, 1, 2 or 3; r is 0 or 1; s is 0 or 1; t is 2, 3, 4, 5 or 6;



is heterocyclyl;

Q is pyrimidinyl pyrazole optionally substituted with one to three R<sup>Z</sup>;

R<sup>1</sup> is independently selected from: 1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl, 2) (C=O)<sub>a</sub>O<sub>b</sub>aryl, 3) C<sub>2</sub>-C<sub>10</sub> alkenyl, 4) C<sub>2</sub>-C<sub>10</sub> alkynyl, 5) (C=O)<sub>a</sub>O<sub>b</sub> heterocyclyl, 6) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl, 7) CO<sub>2</sub>H, 8) halo, 9) CN, 10) OH, 11) O<sub>b</sub>C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl, 12) O<sub>a</sub>(C=O)<sub>b</sub>NR<sup>6</sup>R<sup>7</sup>, 13) NR<sup>c</sup>(C=O)<sub>b</sub>NR<sup>6</sup>R<sup>7</sup>, 14) S(O)<sub>m</sub>R<sup>a</sup>, 15) S(O)<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, 16) NR<sup>c</sup>S(O)<sub>m</sub>R<sup>a</sup>, 17) oxo, 18) CHO, 19) NO<sub>2</sub>, 20) NR<sup>c</sup>(C=O)O<sub>b</sub>R<sup>a</sup>, 21) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl, 22) O(C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl, 23) O(C=O)O<sub>b</sub>aryl, 24) C<sub>1</sub>-C<sub>6</sub>alkyl(C=NR<sup>b</sup>)N(R<sup>b</sup>)<sub>2</sub>, 25) O(C=O)O<sub>b</sub>-heterocycle, 26) O<sub>a</sub>-P=O(OH)<sub>2</sub> and 27) -N=CHN(R<sup>b</sup>)<sub>2</sub>, said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>2</sup> is independently selected from: 1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl, 2) (C=O)<sub>a</sub>O<sub>b</sub>aryl, 3) C<sub>2</sub>-C<sub>10</sub> alkenyl, 4) C<sub>2</sub>-C<sub>10</sub> alkynyl, 5) (C=O)<sub>a</sub>O<sub>b</sub> heterocyclyl, 6) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl, 7) CO<sub>2</sub>H, 8) halo, 9) CN,

10) OH, 11)  $\text{O}_b\text{C}_1\text{-C}_6$  perfluoroalkyl, 12)  $\text{O}_a(\text{C}=\text{O})_b\text{NR}^6\text{R}^7$ , 13)  $\text{NR}^c(\text{C}=\text{O})\text{NR}^6\text{R}^7$ , 14)  $\text{S}(\text{O})_m\text{R}^a$ , 15)  $\text{S}(\text{O})_2\text{NR}^6\text{R}^7$ , 16)  $\text{NR}^c\text{S}(\text{O})_m\text{R}^a$ , 17) CHO, 18)  $\text{NO}_2$ , 19)  $\text{NR}^c(\text{C}=\text{O})\text{O}_b\text{R}^a$ , 20)  $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_1\text{-C}_{10}$  alkyl, 21)  $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_3\text{-C}_8$  cycloalkyl, 22)  $\text{O}(\text{C}=\text{O})\text{O}_b\text{aryl}$ , 23)  $\text{O}(\text{C}=\text{O})\text{O}_b\text{-heterocycle}$ , and 24)  $\text{O}_a\text{-P}=\text{O}(\text{OH})_2$ , said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from  $\text{R}^Z$ ;

$\text{R}^3$  and  $\text{R}^4$  are independently selected from: H,  $\text{C}_1\text{-C}_6$ -alkyl and  $\text{C}_1\text{-C}_6$ -perfluoroalkyl, or

$\text{R}^3$  and  $\text{R}^4$  are combined to form  $-(\text{CH}_2)_t-$  wherein one of the carbon atoms is optionally replaced by a moiety selected from O,  $\text{S}(\text{O})_m$ ,  $-\text{N}(\text{R}^b)\text{C}(\text{O})-$ , and  $-\text{N}(\text{COR}^a)-$ ;

$\text{R}^5$  is independently selected from: 1)  $(\text{C}=\text{O})_a\text{O}_b\text{C}_1\text{-C}_{10}$  alkyl, 2)  $(\text{C}=\text{O})_a\text{O}_b\text{aryl}$ , 3)  $\text{C}_2\text{-C}_{10}$  alkenyl, 4)  $\text{C}_2\text{-C}_{10}$  alkynyl, 5)  $(\text{C}=\text{O})_a\text{O}_b$  heterocyclyl, 6)  $(\text{C}=\text{O})_a\text{O}_b\text{C}_3\text{-C}_8$  cycloalkyl, 7)  $\text{CO}_2\text{H}$ , 8) halo, 9) CN, 10) OH, 11)  $\text{O}_b\text{C}_1\text{-C}_6$  perfluoroalkyl, 12)  $\text{O}_a(\text{C}=\text{O})_b\text{NR}^6\text{R}^7$ , 13)  $\text{NR}^c(\text{C}=\text{O})\text{NR}^6\text{R}^7$ , 14)  $\text{S}(\text{O})_m\text{R}^a$ , 15)  $\text{S}(\text{O})_2\text{NR}^6\text{R}^7$ , 16)  $\text{NR}^c\text{S}(\text{O})_m\text{R}^a$ , 17) oxo, 18) CHO, 19)  $\text{NO}_2$ , 20)  $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_1\text{-C}_{10}$  alkyl, 21)  $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_3\text{-C}_8$  cycloalkyl, and 22)  $\text{O}_a\text{-P}=\text{O}(\text{OH})_2$ , said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from  $\text{R}^Z$ ;

$\text{R}^6$  and  $\text{R}^7$  are independently selected from: 1) H, 2)  $(\text{C}=\text{O})\text{O}_b\text{R}^a$ , 3)  $\text{C}_1\text{-C}_{10}$  alkyl, 4) aryl, 5)  $\text{C}_2\text{-C}_{10}$  alkenyl, 6)  $\text{C}_2\text{-C}_{10}$  alkynyl, 7) heterocyclyl, 8)  $\text{C}_3\text{-C}_8$  cycloalkyl, 9)  $\text{SO}_2\text{R}^a$ , 10)  $(\text{C}=\text{O})\text{NR}^b$ , 11) OH, and 12)  $\text{O}_a\text{-P}=\text{O}(\text{OH})_2$ , said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from  $\text{R}^Z$ , or

$\text{R}^6$  and  $\text{R}^7$  can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 4-7 members in each ring and optionally containing, in addition to the nitrogen, one or more additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from  $\text{R}^Z$ ;

$\text{R}^Z$  is independently selected from: 1)  $(\text{C}=\text{O})_r\text{O}_s(\text{C}_1\text{-C}_{10})\text{alkyl}$ , 2)  $\text{O}_r(\text{C}_1\text{-C}_3)\text{perfluoroalkyl}$ , 3)  $(\text{C}_0\text{-C}_6)\text{alkylene-S}(\text{O})_m\text{R}^a$ , 4) oxo, 5) OH, 6) halo, 7) CN, 8)  $(\text{C}=\text{O})_r\text{O}_s(\text{C}_2\text{-C}_{10})\text{alkenyl}$ , 9)  $(\text{C}=\text{O})_r\text{O}_s(\text{C}_2\text{-C}_{10})\text{alkynyl}$ , 10)  $(\text{C}=\text{O})_r\text{O}_s(\text{C}_3\text{-C}_6)\text{cycloalkyl}$ , 11)  $(\text{C}=\text{O})_r\text{O}_s(\text{C}_0\text{-C}_6)\text{alkylene-aryl}$ , 12)  $(\text{C}=\text{O})_r\text{O}_s(\text{C}_0\text{-C}_6)\text{alkylene-heterocyclyl}$ , 13)  $(\text{C}=\text{O})_r\text{O}_s(\text{C}_0\text{-C}_6)\text{alkylene-N}(\text{R}^b)_2$ , 14)  $\text{C}(\text{O})\text{R}^a$ , 15)  $(\text{C}_0\text{-C}_6)\text{alkylene-CO}_2\text{R}^a$ , 16)  $\text{C}(\text{O})\text{H}$ , 17)  $(\text{C}_0\text{-C}_6)\text{alkylene-CO}_2\text{H}$ , 18)  $\text{C}(\text{O})\text{N}(\text{R}^b)_2$ , 19)  $\text{S}(\text{O})_m\text{R}^a$ , 20)  $\text{S}(\text{O})_2\text{N}(\text{R}^b)_2$ , 21)  $\text{NR}^c(\text{C}=\text{O})\text{O}_b\text{R}^a$ , 22)  $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_1\text{-C}_{10}$  alkyl, 23)  $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_3\text{-C}_8$  cycloalkyl, 24)  $\text{O}(\text{C}=\text{O})\text{O}_b\text{aryl}$ , 25)  $\text{O}(\text{C}=\text{O})\text{O}_b\text{-heterocycle}$ , and 26)  $\text{O}_a\text{-P}=\text{O}(\text{OH})_2$ , said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and

heterocyclyl is optionally substituted with up to three substituents selected from  $R^b$ , OH,  $(C_1-C_6)alkoxy$ , halogen,  $CO_2H$ , CN,  $O(C=O)C_1-C_6$  alkyl, oxo,  $N(R^b)_2$  and  $O_a-P=O(OH)_2$ ;


$R^a$  is: substituted or unsubstituted  $(C_1-C_6)alkyl$ , substituted or unsubstituted  $(C_2-C_6)alkenyl$ , substituted or unsubstituted  $(C_2-C_6)alkynyl$ , substituted or unsubstituted  $(C_3-C_6)cycloalkyl$ , substituted or unsubstituted aryl,  $(C_1-C_6)perfluoroalkyl$ , 2,2,2-trifluoroethyl, or substituted or unsubstituted heterocyclyl; and

$R^b$  is: H,  $(C_1-C_6)alkyl$ , substituted or unsubstituted aryl, substituted or unsubstituted benzyl, substituted or unsubstituted heterocyclyl,  $(C_3-C_6)cycloalkyl$ ,  $(C=O)OC_1-C_6$  alkyl,  $(C=O)C_1-C_6$  alkyl or  $S(O)_2R^a$ ;

$R^c$  is selected from: 1) H, 2)  $C_1-C_{10}$  alkyl, 3) aryl, 4)  $C_2-C_{10}$  alkenyl, 5)  $C_2-C_{10}$  alkynyl, 6) heterocyclyl, 7)  $C_3-C_8$  cycloalkyl, and 8)  $C_1-C_6$  perfluoroalkyl, said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from  $R^z$ , or

or a pharmaceutically acceptable salt or a stereoisomer thereof.

2. (previously presented) The compound according to Claim 1 of the Formula B:



or a pharmaceutically acceptable salt or a stereoisomer thereof.

3. (previously presented) The compound according to Claim 2 wherein:

Q is pyrimidinyl pyrazole optionally substituted with one to three  $R^z$ ;

$R^a$  is:  $(C_1-C_6)alkyl$ ,  $(C_3-C_6)cycloalkyl$ , aryl, or heterocyclyl; and

$R^b$  is: H,  $(C_1-C_6)alkyl$ , aryl, heterocyclyl,  $(C_3-C_6)cycloalkyl$ ,  $(C=O)OC_1-C_6alkyl$ ,  $(C=O)C_1-C_6alkyl$  or  $S(O)_2R^a$ ;

or a pharmaceutically acceptable salt or a stereoisomer thereof.


4. (original) The compound according to Claim 3 wherein:

q is 0;

R<sup>2</sup> is independently selected from: 1) C<sub>1</sub>-C<sub>6</sub> alkyl, 2) aryl, 3) heterocyclyl, 4) CO<sub>2</sub>H, 5) halo, 6) CN, 7) OH, 8) S(O)<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, and 9) O<sub>a</sub>-P=O(OH)<sub>2</sub>, said alkyl, aryl and heterocyclyl optionally substituted with one, two or three substituents selected from R<sup>Z</sup>;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

5. (previously presented) The compound according to Claim 4 of the Formula C:



wherein:

$n$  is 0, 1 or 2;

Q is pyrimidinyl pyrazole optionally substituted with one to three R<sup>2</sup>;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

6. (previously presented) A compound which is selected from:

1-(1-{4-[5-(5-amino-1,3,4-thiadiazol-2-yl)-3-phenylpyridin-2-yl]benzyl}piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine;

1-(1-{4-[5-(1,2,4-oxadiazol-3-yl)-3-phenylpyridin-2-yl]benzyl}piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine;

1-(1-{4-[3-phenyl-5-(1H-1,2,4-triazol-5-yl)pyridin-2-yl]benzyl}piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine;

1-[1-[4-(3-phenyl-5-pyrimidin-2-ylpyridin-2-yl)benzyl]piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine;


1-{1-[4-(5'-phenyl-2,3'-bipyridin-6'-yl)benzyl]piperidin-4-yl}-1H-pyrazolo[3,4-d]pyrimidin-4-amine;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

7-10. (canceled)

11. (original) A compound according to Claim 6 which is:

1-(1-[4-[5-(5-amino-1,3,4-thiadiazol-2-yl)-3-phenylpyridin-2-yl]benzyl]piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine:




or a pharmaceutically acceptable salt or a stereoisomer thereof.

12. (canceled)

13. (original) A compound according to Claim 6 which is:


1-(1-[4-[5-(1,2,4-oxadiazol-3-yl)-3-phenylpyridin-2-yl]benzyl]piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine:



or a pharmaceutically acceptable salt or a stereoisomer thereof.

14. (original) A compound according to Claim 6 which is:

1-{1-[4-(3-phenyl-5-pyrimidin-2-ylpyridin-2-yl)benzyl]piperidin-4-yl}-1H-pyrazolo[3,4-d]pyrimidin-4-amine;



or a pharmaceutically acceptable salt or a stereoisomer thereof.

15. (original) A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 1.

16. (original) A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 6.

17. (currently amended) A method for treating ~~esophageal~~ carcinoma which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

18. (currently amended) A method for treating ~~esophageal~~ carcinoma which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 6.

19-20. (canceled)